WELCOME TO LABOMED
WHO WE ARE
Labomed is a privately owned CDMO service provider (Contract Development and Manufacturing Organization) focused on pharmaceutical services of generics and added–value products of oral liquid dosage forms. We are a combination of specialties with high caliber credentials in the development, manufacturing and commercialization of healthcare products, within EU but also around the globe. Labomed has already accumulated significant know-how, intellectual property rights and projects intended for commercialization and contract manufacturing, mainly through out–licensing and supply models.
9/2020 > Merger Decision
February 2021, Dossiers Submitted:8 & MAs Granted:5
WELCOME TO LABOMED
ABOUT LABOMED
Labomed offers licensing rights and optimized supply agreements for differentiated tailor-made added value generic products. Amongst other, a proprietary pain management portfolio addressing moderate to severe pain is available containing unique presentations and drug combinations. The company integrates contract pharmaceutical manufacturing solutions with drug development capabilities, in order to streamline the pathway from the laboratory to the market.
OUR MISSION
OUR MISSION
OUR VISION
OUR VISION
OUR TARGET
OUR TARGET
OUR SERVICES
WHAT WE DO
Services
A complete range of pharmaceutical services is included in our “boutique-like” philosophy. We offer contract Development, Testing and Manufacturing services at any level, starting from API evaluation, analytical, formulation and process optimization and registration up to EU-GMP tasks during all stages of product lifecycle management.
Manufacturing capabilities
State of the art GMP manufacturing and testing facility, designed flexibly and customizable for small to medium scale batches of (non-sterile) liquids dosage forms. Operated by a highly skilled team of experts in the area, ensures to our sponsors and clients timely and cost-effective realization of their goals.
Consulting
Our extensive experience and deep knowledge of consumer and health care pharmaceutical business environment, enable us to provide you a unique and continuous support to realize a concept idea or a molecule into a finished product and market launch. As contract-basis organization, we aim being a preferred outsourcing partner.
OUR SERVICES
ADDED VALUE PRODUCTS
The Added Value medicines can also be defined as
“Medicines based on known molecules that address
healthcare needs and deliver relevant improvements for patients, healthcare professionals and / or payers”.
The value added to a known medicine could be any of the following:
- > Improved levels of safety, efficacy and/or tolerability.
- > Treatment for new indications or patient sub-populations.
- > Improved treatment administration.
- Drug repurposing: Includes all the re-developmentstrategies.
- Drug reformulation: Reformulation is, by the simple definition of the term, making a particular change in the formulation of the original drug.
- Drug re-profiling / Drug reusing / Drug rediscovery: The usage of known drugs for new diseases.
- Drug repositioning: Process of finding a new indication for a drug or compound (Repositioning goes a step further for generics by creating a stronger product even through the addition of a new indication).
Drug repositioning allows companies:
- To find a non-yet exploited or used value of their medicinal products.
- To differentiate them against generics.
- To create OTC opportunities and protect them against competitors.
OUR PEOPLE
OUR TEAM IS YOUR TEAM!
Labomed is operated by Senior Pharma Executives and supported by a Board of Advisors, who provide significant industry experience as well as access to extensive network of experts and key opinion leaders on pharmaceutical industry and healthcare business in general. Αs of March 2021, the company employs 55 highly educated, technically trained staff. The majority of them being scientists, engineers and of course well-educated and trained operators & workers. Labomed supports the employment of young people by ensuring the personal advancement of its employees, through investment in education and trainings, by the provision of equal opportunities and the continuous improvement of the working environment.
of the company is constantly at a very high level.
GEORGE LIOLIOS
CEO AT LABOMED S.A
Mr. Liolios has been the Chief Executive Officer and Managing Director of five pharmaceutical companies. With a highly decisive approach to business growth, Mr. Liolios offers the benefit of many years of experience in pharmaceutical management and the knowledge to forsee, assess and mitigate risk in a complex, regulated industry.
DIMITRIOS PANAGIOTOPOULOS
PLANT DIRECTOR
BLOG
OUR LATEST NEWS
Labomed is delighted to announce that the European Patent Office has granted the European Patent EP3845215B1
Labomed is delighted to announce that the European Patent Office has granted the European Patent EP3845215B1 covering the Lisdexamfetamine Oral Solution. The product has been developed by Labomed and sponsored by Labomed, Pharma-Data S.A. and Adalvo. This patent will provide the aforementioned parties protection to their
Strategic alliance with HELM AG on a worldwide basis
We are very proud to announce our strategic alliance with HELM AG on a worldwide basis in the co-development, registration, manufacture and commercialization of oral solution products, either generic versions of currently registered product or innovative ideas. This represents a